Mibefradil, a novel T-type and L-type calcium channel blocker, is effective for hypertension and angina but requires caution regarding cytochrome P450 drug interactions.
No takes yet. Share an insight, caveat, or question.
May support mibefradil for hypertension and angina without inotropic effects; leaves open interaction risks and need for prospective safety trials.
Stephen P. Glasser (1998) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: